Genprex partners with US-based CDMO to scale up manufacturing for diabetes gene therapy program - GNPX News | RalliesGenprex partners with US-based CDMO to scale up manufacturing for diabetes gene therapy program
G
GNPX• CDMO agreement to expand diabetes gene therapy manufacturing
- Genprex entered a development and manufacturing agreement with a U.S.-based CDMO to scale up its diabetes gene therapy manufacturing.
- Partnership targets a shift from research-grade output to clinical- and commercial-ready supply in a cGMP facility.
- CDMO to produce drug product for IND-enabling preclinical studies, then supply future clinical trials.
- Program uses an AAV vector to deliver Pdx1 and MafA genes to the pancreas via the pancreatic duct.
•
